Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc. (SLS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A late-stage clinical biopharmaceutical company focused on novel cancer therapeutics. Lead candidates include galinpepimut-S (GPS), a WT1-targeting immunotherapy, and SLS009 (tambiciclib), a CDK9 inhibitor. The company operates as a single segment and has no product sales revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18,012) | $(12,414) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.13) |
| Operating Expenses | $19,881 | $12,936 |
| Interest Income | $1,869 | $522 |
| Cash and Cash Equivalents (End of Period) | $138,343 | $25,397 |
| Net Cash Used in Operating Activities | $(16,434) | $(16,400) |
| Net Cash Provided by Financing Activities | $82,984 | $27,811 |
| Accumulated Deficit | $(293,000) | $(260,539) |
Material Changes vs. Prior Period
- Capital Raise: The company received approximately $82.9 million from the exercise of 48.8 million warrants at a weighted average price of $1.70 per share during the six months ended June 30, 2026. This significantly increased cash balances from $71.8 million to $138.3 million.
- Operating Expenses: Total operating expenses increased by $6.9 million (54%) compared to the prior year period.
- R&D Expenses: Increased by $4.3 million, driven by a $2.3 million rise in manufacturing costs for GPS (preparing for potential BLA filing) and increased clinical trial costs for SLS009.
- G&A Expenses: Increased by $2.6 million, primarily due to a one-time $1.0 million charge for legal fees and arbitration costs related to the 3D Medicines dispute.
- Interest Income: Increased by $1.3 million due to higher cash balances and interest rates.
- Share Count: Weighted average shares outstanding increased significantly due to warrant exercises, diluting the per-share loss despite a higher absolute net loss.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash of $138.3 million to fund operations for at least the next 12 months. The company has a $150 million at-the-market (ATM) sales agreement with TD Cowen but has not sold shares under it yet.
- Clinical Progress:
- GPS: The Phase 3 REGAL study in AML has reached 78 of 80 required events for final analysis. The company is preparing for a potential Biologics License Application (BLA).
- SLS009: Phase 2 trial in relapsed/refractory AML met primary endpoints. A new randomized Phase 2 trial in newly diagnosed, first-line AML began enrollment in Q1 2026. A European study via the IMPACT-AML network is also underway.
- Legal Contingency: The company lost an arbitration against 3D Medicines regarding milestone payments. Claims were dismissed, and the company was ordered to pay approximately $1.0 million in legal and administrative fees, recognized in Q2 2026. $191.5 million in potential future milestones under the 3D Medicines agreement remain unearned.
- Risks: Continued operating losses, dependence on successful clinical outcomes, need for future capital raises, and regulatory uncertainties.
Investor Verification Checklist
- Cash Runway: Verify the $138.3 million cash balance and the 12-month operational runway estimate against current burn rates.
- GPS Trial Status: Monitor the timing of the 80th event in the REGAL study and the subsequent final analysis results.
- SLS009 Enrollment: Track enrollment progress in the new first-line AML Phase 2 trial and the European IMPACT-AML study.
- Legal Exposure: Confirm the payment of the $1.0 million arbitration cost and assess any remaining risks regarding the 3D Medicines agreement.
- Dilution: Review the impact of the recent warrant exercises on share count and the potential dilution from the unused $150 million ATM facility.